Loading...
Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway are expected to be a novel therapy for combating future increases in numbers of malignant pleural mesothelioma (MPM) patients. However, the PD-L1 expression, which is a predictor of the response to ICIs, is unclear in MPM. We studi...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5945532/ https://ncbi.nlm.nih.gov/pubmed/29755688 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25100 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|